tiprankstipranks
Trending News
More News >
Trinity Biotech Plc (TRIB)
NASDAQ:TRIB
Advertisement

Trinity Biotech (TRIB) AI Stock Analysis

Compare
361 Followers

Top Page

TRIB

Trinity Biotech

(NASDAQ:TRIB)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
$1.50
▲(40.19% Upside)
Trinity Biotech's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and high debt levels. While technical analysis shows some positive momentum, the poor valuation metrics further weigh down the score.

Trinity Biotech (TRIB) vs. SPDR S&P 500 ETF (SPY)

Trinity Biotech Business Overview & Revenue Model

Company DescriptionTrinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
How the Company Makes MoneyTrinity Biotech generates revenue primarily through the sale of its diagnostic products to healthcare providers, laboratories, and distributors. The company's key revenue streams include the sale of immunodiagnostic tests, which are used to detect various diseases and conditions, and point-of-care testing devices that provide rapid results. Additionally, Trinity Biotech's revenue is bolstered by strategic partnerships and collaborations with other healthcare companies, which help expand its market reach and enhance its product offerings. The company also benefits from ongoing demand for its diabetes and infectious disease testing products, driving consistent sales growth in a competitive market.

Trinity Biotech Earnings Call Summary

Earnings Call Date:Sep 02, 2025
(Q3-2024)
|
% Change Since: |
Next Earnings Date:Dec 11, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.
Q3-2024 Updates
Positive Updates
Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
TrinScreen HIV Sales Projection
Trinity Biotech reiterated its guidance for TrinScreen sales of approximately $10 million for the full year 2024, reflecting strong market demand.
Reduction in Operating Loss
The operating loss before restructuring and impairment charges decreased to $2.2 million from $4.5 million in Q3 2023, marking a 51% improvement.
NASDAQ Listing Compliance Achieved
The company successfully addressed NASDAQ listing deficiencies, removing an important overhang on its stock.
Cost Reduction Initiatives
SG&A expenses decreased by $1.2 million to $6.5 million in Q3 2024, showcasing effective cost reduction measures.
Negative Updates
Hemoglobin Revenue Decline
Hemoglobin revenues from A1c testing products were lower in Q3 2024 compared to Q3 2023, due to uneven ordering patterns and decreased instrument sales.
Clinical Laboratory Revenue Decrease
Clinical laboratory revenues decreased by 9% compared to Q3 2023, offset by a revenue decrease in the hemoglobin business, which was 70% lower year-over-year.
Net Loss for Q3 2024
The net loss post-tax and interest was $4.8 million in Q3 2024, compared to a $6.7 million loss in the same quarter last year.
Cash Balance Decrease
The cash balance decreased from $5.3 million at June 30 to $2.8 million at the end of September 2024, with cash used by operations of $3.6 million.
Company Guidance
During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.

Trinity Biotech Financial Statement Overview

Summary
Trinity Biotech is facing severe financial challenges with declining revenues, profitability, and a negative equity situation. The company's financial health is weak, requiring strategic interventions for stability and growth.
Income Statement
34
Negative
Trinity Biotech has been experiencing declining revenues and profitability in recent years. The gross profit margin has decreased, and the company has been running at a net loss, with net profit margins consistently negative. The revenue growth rate is negative, indicating shrinking sales year-over-year. Both EBIT and EBITDA margins have also been negative, reflecting operational inefficiencies and challenges in covering operational costs.
Balance Sheet
28
Negative
The balance sheet shows significant financial distress, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, but high total debt levels are concerning. The equity ratio is negative, highlighting an unsustainable financial structure. Return on equity is negative as well, reflecting ongoing losses.
Cash Flow
45
Neutral
Cash flow metrics indicate challenges but also some operational cash inflow improvements in the latest year. Free cash flow remains negative, though the operating cash flow to net income ratio suggests some improvement in cash generation relative to net losses. However, consistent negative free cash flow indicates cash management issues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue61.55M56.83M74.78M92.97M101.98M
Gross Profit21.44M19.45M22.05M38.08M48.58M
EBITDA-16.91M-24.10M-16.71M10.59M21.52M
Net Income-31.79M-24.02M-41.00M875.00K-6.01M
Balance Sheet
Total Assets103.29M59.44M92.10M118.89M130.40M
Cash, Cash Equivalents and Short-Term Investments5.17M3.69M6.58M25.91M27.33M
Total Debt100.76M67.43M58.26M99.16M104.34M
Total Liabilities138.47M83.38M94.28M119.21M132.62M
Stockholders Equity-35.18M-23.95M-2.18M-319.00K-2.22M
Cash Flow
Free Cash Flow-14.26M-14.26M-6.90M4.55M13.56M
Operating Cash Flow-4.19M-11.56M-921.00K13.24M23.75M
Investing Cash Flow-22.97M24.76M-5.98M-8.69M-10.20M
Financing Cash Flow28.81M-16.04M-12.32M-6.02M-2.72M

Trinity Biotech Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.07
Price Trends
50DMA
1.13
Negative
100DMA
0.92
Positive
200DMA
0.84
Positive
Market Momentum
MACD
-0.02
Positive
RSI
41.61
Neutral
STOCH
17.14
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Neutral. The current price of 1.07 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.13, and above the 200-day MA of 0.84, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.61 is Neutral, neither overbought nor oversold. The STOCH value of 17.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TRIB.

Trinity Biotech Risk Analysis

Trinity Biotech disclosed 50 risk factors in its most recent earnings report. Trinity Biotech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Trinity Biotech Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$28.21M-14.40-35.47%27.05%55.03%
48
Neutral
$19.32M77.20%-4.02%-6.31%
44
Neutral
$7.10M-358.07%
41
Neutral
$16.19M-0.04-163.82%-25.02%85.08%
38
Underperform
$10.17M-0.54-352.75%-1.90%87.72%
38
Underperform
$7.08M-0.25547.20%4.99%22.58%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TRIB
Trinity Biotech
1.07
-0.03
-2.73%
PRPO
Precipio
17.42
10.72
160.00%
BNGO
BioNano Genomics
1.66
-25.57
-93.90%
INBS
Intelligent Bio Solutions
1.12
-0.61
-35.26%
MYNZ
Mainz Biomed B.V.
1.55
-8.41
-84.44%
BIAF
bioAffinity Technologies, Inc.
5.29
-57.11
-91.52%

Trinity Biotech Corporate Events

Trinity Biotech Releases 2024 Annual Report
Sep 8, 2025

Trinity Biotech has released its Annual Report for 2024, which includes key documents such as the Company Secretary’s letter, Notice of Annual General Meeting, and AGM Proxy Card. The report, dated September 8, 2025, provides insights into the company’s financial performance, strategic direction, and management structure, highlighting the leadership of CEO John Gillard. This announcement is significant for stakeholders as it outlines the company’s operational and financial status, potentially impacting its market position and investor confidence.

Trinity Biotech Regains Nasdaq Compliance as of September 2025
Sep 2, 2025

On September 2, 2025, Trinity Biotech announced it regained compliance with Nasdaq’s listing requirements, specifically the $1.00 minimum bid price and the minimum market value of publicly held shares. This follows a period of non-compliance noted on March 14, 2025, and subsequent improvements in share price and market value by August 2025. The resolution of these compliance issues is significant for Trinity Biotech’s continued listing on the Nasdaq, which is crucial for maintaining investor confidence and market presence.

Trinity Biotech Receives Approval for Offshore Manufacturing of HIV Test
Aug 20, 2025

On August 20, 2025, Trinity Biotech announced it received regulatory approval to commence offshore and outsourced manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic move is expected to enhance the company’s financial performance by expanding gross margins, freeing up working capital, and reducing fixed costs, thereby supporting broader profitability and growth objectives. The transition to a more cost-effective and scalable production model marks a critical milestone in Trinity Biotech’s transformation strategy, positioning the company for long-term financial health and improved industry positioning.

Trinity Biotech Gains Approval for PreClara™ Preeclampsia Testing Service
Aug 15, 2025

On August 14, 2025, Trinity Biotech announced that it received regulatory approval from the New York State Department of Health to begin offering its FDA-cleared PreClara™ preeclampsia testing service. This approval is a significant milestone in the company’s maternal health strategy, enhancing its position in the U.S. diagnostics market. The PreClara™ test provides crucial insights for managing hypertensive disorders in pregnancy, potentially reducing neonatal costs by over $10 million per 1,000 patients. This development also supports the future introduction of Trinity Biotech’s PrePsia™ technology for early pregnancy risk assessment.

Trinity Biotech Announces Breakthrough in CGM Technology
Aug 12, 2025

On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for its redesigned continuous glucose monitoring (CGM) sensor, marking a significant milestone in diabetes management technology. The trial confirmed that the new needle-free glucose sensor provides accurate readings over a 15-day period without finger-stick calibration, enhancing user convenience and reducing costs. This advancement positions Trinity Biotech to expand access to CGM technology in a growing market, projected to reach $28 billion by 2030, by offering a more affordable and sustainable product.

Trinity Biotech Launches FDA-cleared Preeclampsia Testing Service
Aug 8, 2025

On August 7, 2025, Trinity Biotech announced the launch of its FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test, a significant advancement in maternal health diagnostics. This new testing service, developed in collaboration with Thermo Fisher Scientific, will be available through Trinity Biotech’s New York-based reference laboratory in Q3 2025. The test is designed to provide clinicians with critical insights for managing hypertensive disorders of pregnancy, potentially leading to significant cost savings and improved patient outcomes. This strategic milestone enhances Trinity Biotech’s position in the maternal health sector and reflects its commitment to addressing urgent healthcare needs.

Trinity Biotech Launches CGM+ Platform for AI Wearables Market
Jul 24, 2025

On July 24, 2025, Trinity Biotech announced the unveiling of CGM+, an AI-native platform designed for the $260 billion AI wearables market. This innovative device integrates glucose, cardiovascular, temperature, and activity monitoring into a single wearable, aiming to provide comprehensive health insights through real-time AI analysis. The CGM+ platform is expected to position Trinity Biotech at the forefront of AI-driven healthcare, offering new commercial opportunities and expanding its market presence beyond traditional diagnostics.

Trinity Biotech Achieves Profitability Milestone Amid Strategic Turnaround
Jul 1, 2025

On July 1, 2025, Trinity Biotech announced it had reached a profitability inflection point, a major milestone in its strategic turnaround. The company reported its financial results for the quarter ended March 31, 2025, and projected a positive Adjusted EBITDA from Q3 2025 onwards. This achievement follows significant operational restructuring, including offshoring manufacturing, which has reduced costs and positioned the company for sustainable profitability. Trinity Biotech is now focusing on expanding its product offerings, including diabetes care and HIV tests, and advancing its pipeline of diagnostic tests, such as preeclampsia and prostate cancer tests. The company also continues to develop its next-generation continuous glucose monitoring solution, aiming to capture a significant share of the growing global market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2025